Taste Masking

Developing novel pharmaceutical technology that provides for outstanding taste masking for a broad range of pharmaceuticals including major drug categories such as NSAIDS and statins.

More >>

 

Latest News

2012
30 January Appointment of Business Development Partner
 

2011
19 December Three new orders from Ache Laboratorios Farmaceuticos
15 December Commencement of Distribution Agreement
22 November Holding(s) in Company
22 November Launch of OxpZero™
21 November Result of General Meeting and Grant of Options
03 November Posting of circular in respect of Placing
02 November Placing to raise £1.1m
20 September Interim results to 30 June 2011
31 August Exclusive Option to License of Drug Delivery Technology from The London School of Pharmacy
22 August Shipments of first product to Brazilian pharmaceutical company commence
18 August Change of Adviser
20 May Change of name to Oxford Pharmascience Group
18 May Result of Annual General Meeting
19 April Oxford Nutrascience enters Brazilian pharmaceutical market with commercial agreement
12 April Director Changes
06 April Year End results to 31 December 2010
14 March Holding(s) in Company
14 March Holding(s) in Company
02 February Exclusive License of Drug Delivery Technology from The University of Oxford
 

2010
26 October Patent granted for chewy confectionery compositions
11 October Industry First: Chewy Sweets no longer have to be bad for you
16 September Interim results to 30 June 2010
13 September Commercial agreement with leading provider of outsourced services to the health and beauty markets
29 June Collaboration and exclusivity agreement with world's largest Omega-3 supplier for confectionary chews
24 June Change of Broker
24 May Validation of technology with launch of supplement chews and signing of manufacturing agreement
05 May Subsidiary results to 31 December 2009
01 May Get the great taste of chocolate through a calcium chew
28 April International patent applications made for Chewitab™, novel gels, syrups and
suspension systems
12 April Agreement signed to establish manufacturing capability for Chewitab™
01 March Board changes
12 February Admission to AIM - First Day of Dealings